Avio Smart Market Stack Limited has formalized its strategic partnership with Hyderabad-based Huwel Lifesciences through a Share Subscription cum Shareholders' Agreement, building upon their September 2025 MoU. The collaboration positions the company to capitalize on India's substantial tuberculosis diagnostics market opportunity.

Partnership Structure and Revenue Model

Under the agreement announced on March 2nd, 2026, Avio Smart Market Stack Limited will acquire a minority stake in Huwel Lifesciences while collaborating on business development and project execution. The partnership grants ASMS contractual entitlement to receive a defined share of net project revenues generated from orders secured through its institutional engagement and business development efforts.

Technology Platform and Cost Advantages

Huwel Lifesciences' tuberculosis diagnostic platform has undergone comprehensive evaluation through a Health Technology Assessment conducted by the Department of Health Research under the Ministry of Health & Family Welfare, Government of India. The assessment reveals significant cost advantages for Huwel's Quantiplex® MTB FAST platform:

A key differentiator lies in the platform's compatibility with open RT-PCR systems, enabling utilization of thousands of RT-PCR machines installed across India during the COVID-19 response. This compatibility facilitates rapid deployment without requiring proprietary hardware or significant additional capital expenditure.

Market Opportunity and Scale

The Indian tuberculosis diagnostics market presents substantial scale under the National TB Elimination Programme (NTEP). Key market parameters include:

The Health Technology Assessment findings position Huwel Lifesciences' Quantiplex platform in a potential monopoly position within the public molecular TB diagnostics segment. With the assessment now available, central and state procurement authorities can evaluate the platform for wider adoption under the National TB Elimination Programme.

Management Commentary

Commenting on the development, Mr Vidyasagar Reddy, Managing Director of Avio Smart Market Stack Limited, stated: "The Health Technology Assessment provides important validation for cost-efficient molecular testing within a nationally significant programme. Through this strategic collaboration, we are aligning with scalable public health solutions while building our presence in the life sciences segment."

Strategic Direction

The company has indicated that this collaboration represents the beginning of its broader entry into healthcare and diagnostics-linked opportunities. Avio Smart Market Stack Limited has strategically expanded into the high-growth health-tech sector while building India's largest unified rural operating system, integrating financial inclusion, agriculture, rural commerce, climate solutions, and healthcare to digitally empower farmers and underserved communities across the country.

Bartronics India , now known as Avio Smart Market Stack Limited, announced significant investment decisions following its Board meeting on February 27, 2026. The company has approved revised investment terms with Huwel Lifesciences Private Limited, marking a strategic expansion into the lifesciences sector through both equity participation and revenue-sharing arrangements.

Investment Structure and Terms

The Board approved a comprehensive investment package worth ₹15,00,00,000 (₹15 crore) to be deployed in a structured manner. The investment will be executed through two equal tranches, providing operational flexibility and risk management.

Strategic Business Collaboration

Beyond the equity investment, the agreement establishes a strategic business collaboration framework between the parties. This collaboration focuses on joint identification, development, and execution of projects in the lifesciences sector.

Under the collaboration terms, Avio Smart Market Stack Limited will be entitled to 40% of the Net Project Revenue derived from projects facilitated or supported by the company or its affiliates. This revenue-sharing arrangement provides the company with ongoing income potential from successful project implementations, creating a sustainable business model beyond the initial equity investment.

Governance and Documentation

The Board has approved the execution of a Share Subscription cum Shareholders' Agreement (SSSHA) with Huwel Lifesciences Private Limited and its promoters. This comprehensive agreement will establish detailed terms and conditions governing the investment and define the inter se rights and obligations of all parties involved.

Regulatory Compliance and Timeline

The investment decision follows the company's earlier intimation dated September 23, 2025, and received consent from the Audit Committee prior to Board approval. The transaction does not constitute a related party transaction, as confirmed in the regulatory disclosures.

The Board meeting commenced at 2:30 PM and concluded at 3:15 PM on February 27, 2026. All decisions were made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full regulatory compliance and transparency for stakeholders.